Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

New published data - prostate cancer

02.02.2006


New published data show that bicalutamide (Casodex) 150mg plus radiotherapy significantly extends survival in men with locally advanced prostate cancer compared to radiotherapy alone



New data published in the February 2006 edition of the British Journal of Urology International (BJUI) confirm that bicalutamide 150mg improves the chance of survival by 35 per cent (hazard ratio = 0.65; 95% CI = 0.44 to 0.95, p = 0.03)1 in men with locally advanced prostate cancer (when the disease has spread into the capsule of the prostate or through the prostate into the surrounding tissue) when given bicalutamide 150mg as adjuvant to radiotherapy compared to radiotherapy alone. Bicalutamide 150mg is the only anti-androgen for which this has been shown.1

Also the data from the largest ever treatment study in prostate cancer show that in locally advanced disease, bicalutamide 150mg adjuvant to radiotherapy or radical prostatectomy reduces the risk of disease progression by 31 per cent (hazard ratio = 0.69; 95% CI = 0.58 to 0.82, p < 0.001) leading to a significant survival benefit of 35 per cent when used as adjuvant to radiotherapy.1, In addition, in men with locally advanced prostate cancer, when bicalutamide 150mg was given as monotherapy (alone) there was a 40 per cent reduction in risk, which extended survival free of progression by a median of 2.9 years, showing a trend towards improved survival.2


Commenting on the data, Dr Heather Payne, Consultant in Clinical Oncology, Middlesex Hospital, London stated: "A diagnosis of prostate cancer is truly devastating for the patient. A treatment that both extends a patient’s life and delays the recurrence of the disease whilst maintaining a man’s quality of life is the ultimate goal when managing this condition. This new data from the EPC Trial Programme demonstrates that bicalutamide 150mg meets these vital needs and will have this effect for men with locally advanced prostate cancer."

Results also confirm that treatment with bicalutamide 150mg significantly reduces the risk of bone metastases by 36 per cent in men with locally advanced prostate cancer compared to watchful waiting and by 23 per cent when added to radiotherapy or radical prostatectomy alone.2 Bone metastases are a symptom of disease progression and can include bone and back pain that can cause difficulty in walking and carrying out other daily activities and in more advanced cases can lead to spinal cord compression. By delaying disease progression, bicalutamide 150mg helps men with locally advanced prostate cancer to maintain an active lifestyle.

Patients with locally advanced prostate cancer have a significant risk of their disease progressing, seriously impacting quality of life. Therefore, therapies that improve progression-free survival whilst allowing patients to maintain a normal lifestyle are vital in managing the disease. In addition to improving progression-free survival, bicalutamide 150mg alone demonstrates equal efficacy to castration and provides patients with significant quality of life benefits. Compared with castration, bicalutamide 150mg provides better maintenance of physical capacity and sexual interest.3, Bicalutamide 150mg also maintains bone mineral density, which is lost with castration and is associated with an increased risk of fractures.

The EPC Trial Programme has followed 8,113 patients for an average of 7.4 years in 23 different countries. Patients will continue to be followed up for both disease progression and survival for a minimum period of 10 years after the last patient was enrolled into the study. The 3rd Analysis of the EPC Programme gives additional confirmation that bicalutamide 150mg is a proven treatment option for men with locally advanced prostate cancer delaying disease progression.

In the UK, bicalutamide (Casodex) 150 mg is indicated for patients with locally advanced prostate cancer (T3-T4, any N, MO; T1-T2, N+, MO). Bicalutamide (Casodex) 150mg is indicated as immediate therapy either alone or as adjuvant to treatment by radical prostatectomy or radiotherapy. Bicalutamide (Casodex) 150mg is also indicated for the management of patients with locally advanced, non-metastatic prostate cancer for whom surgical castration or other medical intervention is not considered appropriate or acceptable.

Rosie Allan | alfa
Further information:
http://www.bjui.org
http://www.hillandknowlton.com

More articles from Health and Medicine:

nachricht Biofilm discovery suggests new way to prevent dangerous infections
23.05.2017 | University of Texas at Austin

nachricht Another reason to exercise: Burning bone fat -- a key to better bone health
19.05.2017 | University of North Carolina Health Care

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Can the immune system be boosted against Staphylococcus aureus by delivery of messenger RNA?

Staphylococcus aureus is a feared pathogen (MRSA, multi-resistant S. aureus) due to frequent resistances against many antibiotics, especially in hospital infections. Researchers at the Paul-Ehrlich-Institut have identified immunological processes that prevent a successful immune response directed against the pathogenic agent. The delivery of bacterial proteins with RNA adjuvant or messenger RNA (mRNA) into immune cells allows the re-direction of the immune response towards an active defense against S. aureus. This could be of significant importance for the development of an effective vaccine. PLOS Pathogens has published these research results online on 25 May 2017.

Staphylococcus aureus (S. aureus) is a bacterium that colonizes by far more than half of the skin and the mucosa of adults, usually without causing infections....

Im Focus: A quantum walk of photons

Physicists from the University of Würzburg are capable of generating identical looking single light particles at the push of a button. Two new studies now demonstrate the potential this method holds.

The quantum computer has fuelled the imagination of scientists for decades: It is based on fundamentally different phenomena than a conventional computer....

Im Focus: Turmoil in sluggish electrons’ existence

An international team of physicists has monitored the scattering behaviour of electrons in a non-conducting material in real-time. Their insights could be beneficial for radiotherapy.

We can refer to electrons in non-conducting materials as ‘sluggish’. Typically, they remain fixed in a location, deep inside an atomic composite. It is hence...

Im Focus: Wafer-thin Magnetic Materials Developed for Future Quantum Technologies

Two-dimensional magnetic structures are regarded as a promising material for new types of data storage, since the magnetic properties of individual molecular building blocks can be investigated and modified. For the first time, researchers have now produced a wafer-thin ferrimagnet, in which molecules with different magnetic centers arrange themselves on a gold surface to form a checkerboard pattern. Scientists at the Swiss Nanoscience Institute at the University of Basel and the Paul Scherrer Institute published their findings in the journal Nature Communications.

Ferrimagnets are composed of two centers which are magnetized at different strengths and point in opposing directions. Two-dimensional, quasi-flat ferrimagnets...

Im Focus: World's thinnest hologram paves path to new 3-D world

Nano-hologram paves way for integration of 3-D holography into everyday electronics

An Australian-Chinese research team has created the world's thinnest hologram, paving the way towards the integration of 3D holography into everyday...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Marine Conservation: IASS Contributes to UN Ocean Conference in New York on 5-9 June

24.05.2017 | Event News

AWK Aachen Machine Tool Colloquium 2017: Internet of Production for Agile Enterprises

23.05.2017 | Event News

Dortmund MST Conference presents Individualized Healthcare Solutions with micro and nanotechnology

22.05.2017 | Event News

 
Latest News

How herpesviruses win the footrace against the immune system

26.05.2017 | Life Sciences

Water forms 'spine of hydration' around DNA, group finds

26.05.2017 | Life Sciences

First Juno science results supported by University of Leicester's Jupiter 'forecast'

26.05.2017 | Physics and Astronomy

VideoLinks
B2B-VideoLinks
More VideoLinks >>>